We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current AMLX market cap is 256.37M. The company's latest EPS is USD 0.7188 and P/E is 5.27.
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 102.69M | 108.45M | 88.64M | -1.02M | 416k |
| Operating Income | 18.72M | 1.93M | -11.67M | -68.88M | -193.53M |
| Net Income | 20.89M | 4.73M | -118.79M | -72.7M | -72.7M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 1.43M | 1.43M | 285k | 22.23M | 380.79M |
| Operating Income | -13.55M | -13.55M | -82.69M | -201.34M | 38.8M |
| Net Income | -13.72M | -13.72M | -87.93M | -198.38M | 49.27M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 466.58M | 517.45M | 417.46M | 332.16M | 250.71M |
| Total Liabilities | 48.18M | 84.02M | 93.02M | 70.85M | 54.51M |
| Total Equity | 418.4M | 433.43M | 324.44M | 261.31M | 196.2M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 3.22M | 14.1M | 105.61M | 391.45M | 517.45M |
| Total Liabilities | 20.9M | 8.77M | 17.43M | 50.85M | 84.02M |
| Total Equity | -25.36M | -66.73M | -151.17M | 340.61M | 433.43M |
| Quarter End | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -1.63M | 11.92M | -489k | -67.07M | -108.64M |
| Investing | 71.13M | 92.05M | 819k | -28.14M | 10.67M |
| Financing | 3.31M | 3.54M | 131k | 158k | 238k |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -10.69M | -10.69M | -74.8M | -179.87M | 11.92M |
| Investing | N/A | N/A | -46.41M | -238.99M | 92.05M |
| Financing | 668k | 668k | 158.51M | 431.79M | 3.54M |
| Market Cap | 256.37M |
| Price to Earnings Ratio | 5.27 |
| Price to Sales Ratio | 0.68 |
| Price to Cash Ratio | 1.53 |
| Price to Book Ratio | 0.6 |
| Dividend Yield | - |
| Shares Outstanding | 68.55M |
| Average Volume (1 week) | 533.5k |
| Average Volume (1 Month) | 743.98k |
| 52 Week Change | -74.59% |
| 52 Week High | 19.9488 |
| 52 Week Low | 1.575 |
| Spread (Intraday) | 3.18 (54.83%) |
| Company Name | Amylyx Pharmaceuticals Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.amylyx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
